As individuals age, their bodies often lose resilience, leading to increased vulnerability to health issues. This condition, known as frailty, affects up to 24% of people over the age of 65, significantly diminishing their independence and complicating daily activities.
While traditional methods like strength training and improved nutrition have been the mainstay for combating frailty, a groundbreaking therapy is now emerging that targets the biological underpinnings of the condition.
Researchers have introduced an innovative intravenous treatment named laromestrocel, derived from stem cells obtained from the bone marrow of healthy donors aged 18 to 45. These stem cells not only have the potential to develop into muscle or cartilage but also release factors that reduce inflammation and repair damaged blood vessels.
Clinical Trials: A Step Forward
To assess the effectiveness of these youthful stem cells, a clinical trial involving 148 older adults, aged between 74 and 76, was conducted. Participants, all experiencing mild to moderate frailty, were randomly assigned to receive either a placebo or varying doses of laromestrocel. Their endurance was evaluated using a standard six-minute walking test over several months.
Results published in the journal Cell Stem Cell indicated significant improvements in mobility, with those receiving higher doses showing enhanced walking distances over time. Notably, individuals receiving the highest dose were able to walk 63.4 meters farther than those given a placebo, and they reported an overall better quality of life.
The Mechanism Behind the Breakthrough
The mechanism of action for laromestrocel is intriguing. It appears to inhibit harmful enzymes known as matrix metalloproteinases, which can damage a critical receptor on blood vessels called TIE2. By preventing this damage, the therapy may help rejuvenate the vascular system, which is essential for supplying muscles with the nutrients necessary for endurance.
Additionally, researchers have identified a potential biomarker, soluble TIE2 (sTIE2), which could predict who would benefit most from the treatment. Elevated levels of sTIE2 indicate compromised blood vessels and inflammation, making it a valuable tool for personalizing treatment.
Challenges and Future Prospects
Despite the promise of this therapy, scaling production to meet the needs of an aging population poses challenges. The extraction of stem cells is a minor surgical procedure, but researchers can amplify a single donation to produce billions of cells, creating a sustainable supply that minimizes the burden on young donors.
While the therapy shows potential, experts caution against relying solely on stem cell treatments. Traditional walking programs have also demonstrated significant benefits in enhancing mobility without the associated costs of new therapies.
Nevertheless, optimism remains high, with ongoing efforts to increase the availability of these stem cells. As Joshua Hare from Longeveron states, "There is a lot of work ongoing regarding the ability to make these kinds of stem cells in large quantities, and I am confident the need will be met."